Telix Pharmaceuticals Limited
TLX
$9.43
-$0.12-1.26%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 195.18M | 195.18M | 136.60M | 140.46M | 122.85M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 195.18M | 195.18M | 136.60M | 140.46M | 122.85M |
| Cost of Revenue | 100.29M | 100.29M | 52.46M | 53.94M | 51.04M |
| Gross Profit | 94.89M | 94.89M | 84.14M | 86.52M | 71.81M |
| SG&A Expenses | 48.35M | 48.35M | 36.43M | 37.46M | 33.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 6.33M | 6.33M | 174.00K | 178.90K | 3.46M |
| Total Operating Expenses | 195.76M | 195.76M | 125.05M | 128.58M | 117.44M |
| Operating Income | -580.00K | -580.00K | 11.55M | 11.87M | 5.41M |
| Income Before Tax | -2.42M | -2.42M | 6.96M | 7.16M | 5.83M |
| Income Tax Expenses | -1.27M | -1.27M | 361.30K | 371.50K | -1.77M |
| Earnings from Continuing Operations | -1.15M | -1.15M | 6.60M | 6.79M | 7.60M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.15M | -1.15M | 6.60M | 6.79M | 7.60M |
| EBIT | -580.00K | -580.00K | 11.55M | 11.87M | 5.41M |
| EBITDA | 2.93M | 2.93M | 12.20M | 12.54M | 7.00M |
| EPS Basic | 0.00 | 0.00 | 0.02 | 0.02 | 0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.02 | 0.02 | 0.01 |
| EPS Diluted | 0.00 | 0.00 | 0.02 | 0.02 | 0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.02 | 0.02 | 0.01 |
| Average Basic Shares Outstanding | 337.20M | 337.20M | 334.73M | 334.73M | 658.17M |
| Average Diluted Shares Outstanding | 337.20M | 337.20M | 351.47M | 351.47M | 684.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |